A new study led by the Indian Council of Medical Research (ICMR) has revealed that women suffering from metabolic syndrome (MeS) face a significantly higher risk of developing gynaecological cancers, including ovarian, endometrial, cervical, vaginal, and vulvar cancers. The findings, published in the Indian Journal of Medical Research on October 10, cast a spotlight on the rising prevalence of MeS among Indian women and its urgent implications for public health.
Metabolic syndrome is defined by a cluster of metabolic abnormalities—obesity, high blood sugar, hypertension, elevated triglycerides, and low HDL cholesterol—all of which are becoming worryingly common in India. The study points out that about 35% of adult women in the country now live with MeS, compared to 26% of men, with rates climbing further with age.
Researchers from ICMR’s National Institute of Reproductive and Child Health (NIRRCH) in Mumbai found that women diagnosed with MeS are nearly three times more likely to develop ovarian cancer and almost twice as likely to suffer from uterine (endometrial) cancer. The risk for vaginal and vulvar cancers also increases, though to a lesser extent. These results are particularly concerning given that gynaecological cancers, including cervical and breast cancers, remain among the leading killers of women in India.
“It was surprising to note that despite the growing burden of MeS and related non-communicable diseases, there’s a lack of Indian-specific studies on this topic,” remarked Dr. Susan Idicula-Thomas, the study’s corresponding author. Co-investigator Dr. Denny John emphasized the importance of integrating women with metabolic disorders into preventive health programmes: “This approach is vital for both preventing and detecting gynaecological cancers early in India.”
The research highlights a critical need for data-driven health policies and tailored screening strategies to address this often-overlooked risk for Indian women.
